Viewing Study NCT06810050


Ignite Creation Date: 2025-12-24 @ 5:03 PM
Ignite Modification Date: 2025-12-24 @ 5:03 PM
Study NCT ID: NCT06810050
Status: RECRUITING
Last Update Posted: 2025-02-05
First Post: 2025-01-23
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
Sponsor: CAGE Bio Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module